Quick Answer
Cellectis S.A. reported R&D Expense of $93.52 million for fiscal year 2025.
Cellectis S.A. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $93.52M | +3.3% |
| 2024 | $90.54M | +3.3% |
| 2023 | $87.65M | -10.1% |
| 2022 | $97.50M | -17.3% |
| 2021 | $117.84M | +52.9% |
| 2020 | $77.05M | -16.3% |
| 2019 | $92.04M | +20.2% |
| 2018 | $76.57M | -3.4% |
| 2017 | $79.23M | +1.0% |
| 2016 | $78.46M | +34.9% |
| 2015 | $58.15M | — |
- Cellectis S.A. showed an increase of +3.3% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, Cellectis S.A.’s r&d expense has grown by 60.8% (from $58.15 million to $93.52 million).
- The most recent figure is from Cellectis S.A.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: